HRAS G12D

CI-VAR-00001608Explore in graph →CIViC 1387

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Head and Neck Neoplasm1
HRAS G12D	Erlotinib	Predictive	D	Supports Resistance	—	submitted	EID3697 In an in vitro study, a H31 cell line expressing HRAS G12D mutation demonstrated decreased sensitivity to erlotinib treatment (GI50s >3.50 uM vs. 0.067�0.184 uM) compared to UM-SCC-19 or MSK-922 or M… (full text at CIViC) PMID 24123531 · Hah et al., 2014 · Open in CIViC	civic
Skin Squamous Cell Carcinoma1
HRAS G12D	Vemurafenib	Predictive	C	Supports Resistance	—	submitted	EID3698 In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.